Jiankang Hu

No. 19 Yuquan Road
Yuquan, 100049, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Rapid Identification of a Potent, Selective, and Orally Active p300/CBP Bromodomain Inhibitor Bearing an Imidazo[1,2-a]pyridine Scaffold via a Highly Efficient Four-Step Synthesis.

Rapid Identification of a Potent, Selective, and Orally Active p300/CBP Bromodomain Inhibitor Bearing an Imidazo[1,2-a]pyridine Scaffold via a Highly Efficient Four-Step Synthesis.

Journal: Journal of medicinal chemistry

Published: July 17, 2026

Discovery of a Highly Potent and Efficient BRD9 Degrader with Strong In Vivo Antitumor Activity.

Discovery of a Highly Potent and Efficient BRD9 Degrader with Strong In Vivo Antitumor Activity.

Journal: Journal of medicinal chemistry

Published: May 28, 2026

Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy.

Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy.

Journal: Journal of medicinal chemistry

Published: March 04, 2026

Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-Resistant Prostate Cancer.

Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-Resistant Prostate Cancer.

Journal: Journal of medicinal chemistry

Published: January 02, 2025

Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors.

Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors.

Journal: Journal of medicinal chemistry

Published: November 27, 2024

Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.

Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.

Journal: Journal of medicinal chemistry

Published: June 03, 2024

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity.

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity.

Journal: Journal of medicinal chemistry

Published: April 22, 2024

CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond.

CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond.

Journal: Journal of medicinal chemistry

Published: March 22, 2024

Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.

Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.

Journal: Bioorganic chemistry

Published: September 24, 2023

Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.

Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.

Journal: Biochemical and biophysical research communications

Published: June 28, 2022

Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.

Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.

Journal: European journal of medicinal chemistry

Published: January 07, 2022

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

Journal: Journal of medicinal chemistry

Published: December 28, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026